var data={"title":"Pentamidine (oral inhalation): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pentamidine (oral inhalation): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/785168?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pentamidine-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Pentamidine (oral inhalation): Drug information&quot;</a> and <a href=\"topic.htm?path=pentamidine-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pentamidine (oral inhalation): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486476\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Nebupent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45043322\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Miscellaneous</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antifungal Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiprotozoal</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45043326\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=pentamidine-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Pentamidine (oral inhalation): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b><i>Pneumocystis jirovecii</i> (PCP); prophylaxis (primary and secondary):</b> Limited data available: <b>Note:</b> For patients intolerant to sulfamethoxazole and trimethoprim. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;5 years who are HSCT recipients: Inhalation: 9 mg/kg (maximum dose: 300 mg/dose) once monthly (every 4 weeks) via Respigard II nebulizer ([CDC/IDSA [Tomblyn 2009]) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;5 years and Adolescents; independent of HIV status: Inhalation: 300 mg once monthly (every 4 weeks) via Respirgard II nebulizer (DHHS [adult and pediatric] 2013; <i>Red Book</i> [AAP] 2015; CDC/IDSA [Tomblyn 2009]) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b><i>Pneumocystis jirovecii</i> (PCP), prophylaxis (primary and secondary):</b> Inhalation: 300 mg/dose every 4 weeks via Respirgard II nebulizer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustment provided in the manufacturer's labeling; has not been studied.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486544\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Inhalation, as isethionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nebupent: 300 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486479\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45043328\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Oral inhalation: Safe and effective administration via nebulization in children is dependent on patients wearing an appropriately sized pediatric face mask. Deliver via Respirgard II nebulizer until nebulizer is emptied (30 to 45 minutes). Use appropriate precautions to minimize exposure to health care personnel; refer to individual institutional policy. The manufacturer recommends the use of freshly prepared solutions for inhalation. Do not mix with other nebulizer solutions. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486509\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The manufacturer recommends the use of freshly prepared solutions for inhalation; however, may be stored for up to 48 hours in the vial at room temperature if protected from light. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45043323\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Prevention of pneumonia caused by <i>Pneumocystis jirovecii </i>(formerly <i>carinii</i>) (PCP) (FDA approved in ages &ge;17 years and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486500\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Chest pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Night sweats</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Decreased appetite, diarrhea, dysgeusia, nausea, oral candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Herpes virus infection, herpes zoster, infection, influenza</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Bronchitis, bronchospasm, cough, dyspnea, pharyngitis, sinusitis, upper respiratory tract infection, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever, night sweats</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Rare but important or life-threatening: Abscess (oral), abdominal cramps, andominal pain, acute pancreatitis, acute rhinitis, ageusia, amnesia, anaphylaxis, anxiety, arthralgia, asthma, bacterial pneumonia, blepharitis, blurred vision, body odor, bronchitis, cerebrovascular accident, chest congestion, chest tightness, colitis, confusion, conjunctivitis, constipation, contact lens intolerance, cyanosis, cytomegalovirus disease (including colitis and retinitis), cytopenia, depression, dermatitis, desquamation, diabetes mellitus, disuption of body temperature regulation, drowsiness, dry hair, dyspepsia, dyspnea, emotional lability, encephalitis (viral), eosinophilia, eosinophilic pneumonitis, erythema, esophageal candidiasis, esophagitis, eye pain, facial edema, flank pain, gag reflex, gastritis, gastric ulcer, gingivitis, gout, hallucination, hematochezia, hemianopia, hemoptysis, hepatic insufficiency, hepatitis, hepatomegaly, herpes virus infection (pharyngeal), hiatal hernia, histoplasmosis, hyperglycemia, hyperkalemia, hypersensitivity reaction, hypertension, hyperventilation, hypocalcemia, hypoesthesia, hypoglycemia, hypotension, hypothermia, hypoxia, increased blood urea nitrogen, increased bronchial secretions, increased serum creatinine, infection (mycoplasma), insomnia, interstitial pneumonitis, Kaposi's sarcoma, laryngitis, laryngospasm, lethargy, lower extremity edema, melena, meningitis (cryptococcal infection), myalgia, nasal congestion, nephritis, nervousness, neuralgia, neuropathy, neutropenia, oral herpes, oral mucosa ulcer, otitis, palpitations, pancreatitis, pancytopenia, paranoia, paresthesia, peripheral neuropathy, pleurisy, pneumothorax, pruritus, pulmonary disease, rales, renal failure, renal insufficiency, renal pain, rhinitis, seizure, sepsis (central venous line-related), serious infection (extrapulmonary pneumocystosis), SIADH, sialorrhea, skin rash, splenomegaly, Stevens-Johnson syndrome, ST segment changes on ECG, syncope, tachycardia, tachypnea, thrombocytopenia, tonsillitis, torsades de pointes, tremor, tuberculosis, unsteady gait, urinary incontinence, urticaria, vasodilation, vasculitis, ventricular tachycardia, vertigo, vomiting, xeroderma, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486495\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pentamidine isethionate or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486496\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Asthma: Use inhalation formulation with caution in patients with asthma. May induce bronchospasm or cough, especially in patients with a smoking or asthma history (an inhaled bronchodilator prior to pentamidine may ameliorate symptoms).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pancreatitis: Use with caution in patients with a history of pancreatic disease or elevated amylase/lipase levels; acute pancreatitis (with fatality) has been reported. Discontinue inhalational pentamidine if signs/symptoms of acute pancreatitis occur. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; PCP: Acute PCP may develop despite aerosolized pentamidine prophylaxis. Although rare, extrapulmonary PCP disease may occur and has been associated with aerosolized pentamidine. Use appropriate precautions to minimize exposure to healthcare personnel; refer to individual institutional policy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Adverse effects: Injection: According to the manufacturer, extent and consequence of pentamidine accumulation following chronic inhalation therapy are not known. Patients receiving pentamidine inhalation should be closely monitored for the development of serious adverse reactions that have occurred in patients receiving parenteral pentamidine, including hypotension, hypoglycemia, hyperglycemia, hypocalcemia, anemia, thrombocytopenia, leukopenia, hepatic or renal dysfunction, ventricular tachycardia (eg, torsade de pointes), pancreatitis, Stevens-Johnson syndrome, hyperkalemia and abnormal ST segment of ECG.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486505\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486502\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=104535&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486490\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486491\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if clinically significant concentrations reach the fetus when administered via the aerosolized route. Information related to fetal outcomes following maternal use of pentamidine is limited. If administered via the aerosolized route, maternal serum concentrations are lower, minimizing the exposure to the fetus (Gates 1993; Nanda 1992; Sperling 1992). Concern regarding occupational exposure and theoretical risk to pregnant health care workers has been discussed in the literature. Pregnant health care workers should avoid aerosolized exposure if possible (Conover 1988; Ito 1994; Smaldone 1991).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Aerosolized pentamidine may be used as an alternative agent for the prophylaxis of <i>Pneumocystis jirovecii</i> pneumonia in pregnant females with HIV infection who either cannot tolerate the preferred therapy or who wish to avoid it during the first trimester of pregnancy (HHS [OI; adult] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45043329\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic monitoring of liver function tests, renal function tests, blood glucose, serum potassium and calcium, CBC with differential and platelet count, ECG, blood pressure </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486513\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with microbial RNA/DNA, phospholipids and protein synthesis, through inhibition of oxidative phosphorylation and/or interference with incorporation of nucleotides and nucleic acids into RNA and DNA</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486515\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Inhalation: Limited systemic absorption with chronic therapy, potential accumulation and systemic effects unknown</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Binds to tissues and plasma protein; high concentrations are found in the liver, kidney, adrenals, spleen, lungs, and pancreas; poor penetration into CNS; following oral inhalation, high concentrations are found in bronchoalveolar fluid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: 5 to 8 hours; IM: 7 to 11 hours; may be prolonged with severe renal impairment </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44486546\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Nebupent Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (1): $200.27</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45524663\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Pentacarinat (FR, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;<i>Pneumocystis jiroveci</i> (formerly <i>carinii</i>) Pneumonia (PCP).&rdquo; Available at <a href=\"http://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Pneumocystis_jiroveci.pdf\" target=\"_blank\">http://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Pneumocystis_jiroveci.pdf</a>. Last accessed September 15, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Comtois R, Pouliot J, Gervais S, et al, &ldquo;High Pentamidine Levels Associated With Hypoglycemia and Azotemia in a Patient With <i>Pneumocystis carinii</i> Pneumonia,&rdquo; <i>Diagn Microbiol Infect Dis</i>, 1992, 15(6):523-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/1424505/pubmed\" target=\"_blank\" id=\"1424505\">1424505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conover B, Goldsmith JC, Buehler BA, et al, &quot;Aerosolized Pentamidine and Pregnancy,&quot; <i>Ann Intern Med</i>, 1988, 109(11):927.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/3190049/pubmed\" target=\"_blank\" id=\"3190049\">3190049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fortunato SJ and Bawdon RE, &quot;Determination of Pentamidine Transfer in the <i>in vitro</i> Perfused Human Cotyledon With High-Performance Liquid Chromatography,&quot; <i>Am J Obstet Gynecol</i>, 1989, 160(3):759-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/2929699/pubmed\" target=\"_blank\" id=\"2929699\">2929699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gates HS Jr and Barker CD, &quot;<i>Pneumocystis carinii</i> Pneumonia in Pregnancy. A Case Report,&quot; <i>J Reprod Med</i>, 1993, 38(6):483-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/8331631/pubmed\" target=\"_blank\" id=\"8331631\">8331631</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goa KL and Campoli-Richards DM, &ldquo;Pentamidine Isethionate. A Review of Its Antiprotozoal Activity, Pharmacokinetic Properties and Therapeutic Use in <i>Pneumocystis carinii</i> Pneumonia,&rdquo; <i>Drugs</i>, 1987, 33(3):242-58.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hand IL, Wiznia AA, Porricolo M, et al, &ldquo;Aerosolized Pentamidine for Prophylaxis of <i>Pneumocystis carinii</i> Pneumonia in Infants With Human Immunodeficiency Virus Infection,&rdquo; <i>Pediatr Infect Dis J</i>, 1994, 13(2):100-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/8190532/pubmed\" target=\"_blank\" id=\"8190532\">8190532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Updated April 29, 2016. Accessed May 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. September 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed October 8, 2015</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hughes WT, &ldquo;<i>Pneumocystis carinii</i> Pneumonia: New Approaches to Diagnosis, Treatment, and Prevention,&rdquo; <i>Pediatr Infect Dis J</i>, 1991, 10(5):391-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/2067889/pubmed\" target=\"_blank\" id=\"2067889\">2067889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S and Koren G, &ldquo;Estimation of Fetal Risk From Aerosolized Pentamidine in Pregnant Healthcare Workers,&rdquo; <i>Chest</i>, 1994, 106(5):1460-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/7956402/pubmed\" target=\"_blank\" id=\"7956402\">7956402</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Masur H, &ldquo;Prevention and Treatment of <i>Pneumocystis</i> Pneumonia,&rdquo; <i>N Engl J Med</i>, 1992, 327(26):1853-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/1448123/pubmed\" target=\"_blank\" id=\"1448123\">1448123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monk JP and Benfield P, &ldquo;Inhaled Pentamidine. An Overview of Its Pharmacological Properties and a Review of Its Therapeutic Use in <i>Pneumocystis carinii</i> Pneumonia,&rdquo; <i>Drugs</i>, 1990, 39(5):741-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/2191850/pubmed\" target=\"_blank\" id=\"2191850\">2191850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nanda D, Tannenbaum I, Landesman S, et al, &quot;Pentamidine Prophylaxis in Pregnancy,&quot; <i>Am J Obstet Gynecol</i>, 1992, 166:387.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NebuPent  (pentamidine isethionate) [prescribing information]. Schaumburg, IL: American Pharmaceutical Partners Inc.; December 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pelucio MT, Rothenhaus T, Smith M, et al, &ldquo;Fatal Pancreatitis as a Complication of Therapy for HIV Infection,&rdquo; <i>J Emerg Med</i>, 1995, 13(5):633-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/8530781/pubmed\" target=\"_blank\" id=\"8530781\">8530781</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwebke K, Fletcher CV, Acosta EP, et al, &quot;Pentamidine Concentrations in a Mother With AIDS and in Her Neonate,&quot; <i>Clin Infect Dis</i>, 1995, 20(6):1569-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/7548518/pubmed\" target=\"_blank\" id=\"7548518\">7548518</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh G, el-Gadi SM, and Sparks RA, &ldquo;Pancreatitis Associated With Aerosolized Pentamidine,&rdquo; <i>Genitourin Med</i>, 1995, 71(2):130-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/7744406/pubmed\" target=\"_blank\" id=\"7744406\">7744406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smaldone GC, Vinciguerra C, and Marchese J, &quot;Detection of Inhaled Pentamidine in Health Care Workers,&quot; <i>N Engl J Med</i>, 1991, 325(12):891-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/1875979/pubmed\" target=\"_blank\" id=\"1875979\">1875979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sperling RS, Stratton P, O'Sullivan MJ, et al, &quot;A Survey of Zidovudine Use in Pregnant Women With Human Immunodeficiency Virus Infection,&quot; <i>N Engl J Med</i>, 1992, 326(13):857-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/1542322 /pubmed\" target=\"_blank\" id=\"1542322 \">1542322 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.  <i>Biol Blood Marrow Transplant</i>. 2009; 15(10):1143-1238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 104535 Version 22.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F44486476\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F45043322\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F45043326\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F44486544\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F44486479\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45043328\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F44486509\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45043323\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F44486500\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F44486495\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F44486496\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F44486505\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F44486502\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F44486490\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F44486491\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45043329\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F44486513\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F44486515\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F44486546\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45524663\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/104535|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pentamidine-oral-inhalation-drug-information\" class=\"drug drug_general\">Pentamidine (oral inhalation): Drug information</a></li><li><a href=\"topic.htm?path=pentamidine-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">Pentamidine (oral inhalation): Patient drug information</a></li></ul></div></div>","javascript":null}